Abemaciclib

VERZENIO®

Overview

Abemaciclib is an experimental therapy being developed by Eli Lilly and it acts as a CDK inhibitor selective for CDK4 and CDK6.

SparkCures ID 325
Developed By Eli Lilly and Company
Brand Name Verzenio®
Generic Name Abemaciclib
Treatment Classifications
  • Cyclin-Dependent Kinase Inhibitor

Clinical Trials

All Clinical Trials

View all active clinical trials around the US.

Early Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.

Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

Smoldering Myeloma
Monoclonal Gammopathy of Undetermined Significance (MGUS)

Resources

There are no resources, links or videos to display for this treatment.